NCT07199777View on ClinicalTrials.gov

A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

March 31, 2027

Conditions

Diabetic Macular EdemaDME

Interventions

DRUG

SNP318

Once daily, oral administration

DRUG

Placebo

Once daily, oral administration

All Listed Sponsors

lead

SciNeuro

INDUSTRY